Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4

NCT06560645 is registered in ClinicalTrials.gov with Prelude Therapeutics as lead sponsor.

NCT NCT06560645
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06560645 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4
Lead sponsor
Prelude Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
November 4, 2024
Completion date
January 28, 2026
Enrollment
42 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, esophageal adenocarcinoma, esophageal squamous cell carcinoma, gastric adenocarcinoma, gastric squamous cell carcinoma, gastroesophageal junction adenocarcinoma, gastroesophageal junction squamous cell carcinoma, metastatic solid tumor, non-small cell lung carcinoma, smarca4 mutation